Femasys (NASDAQ:FEMY – Get Free Report) had its target price cut by stock analysts at Lake Street Capital from $30.00 to $10.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital’s price target would suggest a potential upside of 352.28% from the company’s current price.
FEMY has been the topic of a number of other research reports. Maxim Group cut their price objective on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research report on Friday. Weiss Ratings upgraded shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Finally, Wall Street Zen raised Femasys to a “hold” rating in a research note on Saturday, June 13th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.
Check Out Our Latest Analysis on FEMY
Femasys Trading Up 2.4%
Femasys (NASDAQ:FEMY – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.02). Femasys had a negative net margin of 534.36% and a negative return on equity of 208.04%. The business had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.73 million.
Insider Buying and Selling
In related news, CFO Dov Elefant acquired 15,625 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the purchase, the chief financial officer owned 15,625 shares in the company, valued at $50,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the acquisition, the chief executive officer directly owned 15,625 shares in the company, valued at $50,000. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 38,750 shares of company stock valued at $124,000 over the last quarter. 7.75% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers bought a new stake in shares of Femasys during the fourth quarter valued at about $36,000. Kovack Advisors Inc. bought a new position in shares of Femasys in the 4th quarter worth $27,000. State Street Corp increased its holdings in shares of Femasys by 43.5% in the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after buying an additional 24,500 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Femasys during the 4th quarter valued at $62,000. Finally, HRT Financial LP bought a new stake in shares of Femasys during the 4th quarter worth $30,000. Institutional investors own 65.27% of the company’s stock.
Femasys Company Profile
Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.
The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.
Read More
- Five stocks we like better than Femasys
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
